Rescue of HIV-1 long-time archived X4 strains to escape maraviroc

Antiviral Res. 2011 Dec;92(3):488-92. doi: 10.1016/j.antiviral.2011.10.003. Epub 2011 Oct 13.

Abstract

Entry of Human Immunodeficiency Virus type 1 (HIV-1) into target cells is mediated by the CD4 receptor and a coreceptor, CCR5 or CXCR4. Maraviroc interferes with HIV entry by binding the CCR5 coreceptor. Virological failure to maraviroc-containing regimens can occur through the emergence of resistance, or through tropism evolution and broadened coreceptor usage. In the latter case, the physiological relevance of minority strains is a major concern. Here we report a retrospective analysis of coreceptor-usage and evolution based on 454-ultra-deep-sequencing of plasma and Peripheral Blood Mononuclear Cell (PBMC)-derived envelope V3-loops, accounting for coreceptor usage, from a patient who failed a maraviroc-containing regimen through the emergence of X4 strains. The X4 maraviroc-escape variant resulted from recombination between a long time archived proviral sequence from 2003 (5'-portion, including the V3-loop) and the dominant R5 strains circulating in plasma at the time of maraviroc-treatment initiation (3'-portion). Phylogenetic analyses and BEAST modeling highlighted that an early diverse viral quasispecies underwent a severe bottleneck following reinitiation of HAART and repeated IL-2 cycles between 1999 and 2001, leading to the transient outgrowth and archiving of one highly homogeneous X4 population from plasma, and to the expansion in plasma of one PBMC-derived R5 strain. Under maraviroc selective pressure, the early, no longer detectable X4 strains archived in PBMC were partially rescued to provide X4-determinants to the main circulating strain.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Base Sequence
  • CCR5 Receptor Antagonists
  • CD4 Lymphocyte Count
  • Cyclohexanes / pharmacology
  • Cyclohexanes / therapeutic use*
  • Genotype
  • HIV Fusion Inhibitors / pharmacology
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Leukocytes, Mononuclear / virology
  • Maraviroc
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Phylogeny
  • Receptors, CCR5 / genetics
  • Receptors, CXCR4 / genetics
  • Receptors, CXCR4 / metabolism
  • Sequence Alignment
  • Treatment Failure
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*
  • Viral Load
  • Viral Tropism

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Receptors, CCR5
  • Receptors, CXCR4
  • Triazoles
  • Maraviroc